Encompass Health Co. (NYSE:EHC) EVP Sells $1,220,739.42 in Stock

Encompass Health Co. (NYSE:EHC) EVP John Patrick Darby sold 14,543 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $83.94, for a total transaction of $1,220,739.42. Following the completion of the sale, the executive vice president now owns 84,773 shares in the company, valued at $7,115,845.62. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Encompass Health Trading Down 0.7 %

NYSE:EHC opened at $85.32 on Thursday. Encompass Health Co. has a 12-month low of $57.55 and a 12-month high of $86.60. The firm has a market cap of $8.59 billion, a PE ratio of 23.18, a price-to-earnings-growth ratio of 1.30 and a beta of 0.92. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. The stock has a fifty day moving average price of $79.54 and a 200 day moving average price of $71.95.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the company earned $0.88 EPS. Encompass Health’s revenue for the quarter was up 13.4% compared to the same quarter last year. Sell-side analysts anticipate that Encompass Health Co. will post 4.1 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Monday, July 1st will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Friday, June 28th. Encompass Health’s dividend payout ratio (DPR) is presently 16.22%.

Institutional Investors Weigh In On Encompass Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Principal Securities Inc. acquired a new position in shares of Encompass Health during the fourth quarter worth $25,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Encompass Health by 360.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after acquiring an additional 317 shares during the last quarter. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Encompass Health during the 4th quarter worth about $30,000. GAMMA Investing LLC purchased a new stake in Encompass Health during the fourth quarter worth approximately $33,000. Finally, C M Bidwell & Associates Ltd. acquired a new position in Encompass Health in the third quarter valued at approximately $35,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on EHC. Royal Bank of Canada reissued an “outperform” rating and issued a $83.00 price target on shares of Encompass Health in a research note on Friday, February 9th. Truist Financial upped their price target on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research note on Friday, February 9th. Barclays lifted their price objective on Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. William Blair reissued an “outperform” rating on shares of Encompass Health in a research note on Wednesday, February 7th. Finally, Mizuho lifted their target price on Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Encompass Health has an average rating of “Buy” and a consensus price target of $90.29.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.